by Laura Turbay | Sep 23, 2024
Small-cap biotech stocks plundered after a 2021 wild-run, but investors are hopeful that interest rate cuts and positive test results in oncology and autoimmune treatments will be the right prescription for the biopharma market. That would be welcome news for...
by Mariam Kiparoidze | Nov 27, 2023
Photo: Wikimedia Commons Covid made Pfizer a household name and sent its revenues and profits soaring. Now flush with cash and amid its post-covid slump, Pfizer is betting that its next blockbuster drug could be a cancer treatment. The pharma giant made headlines...
by Mariam Kiparoidze | Nov 3, 2023
Photo credit:Wikimedia Commons Pfizer reported a loss in the third quarter as it tries to adapt to the faltering demand on its Covid-19 drug and vaccines. Pfizer reported a net loss of $2.38 billion last quarter, missing analyst expectations, the pharmaceutical giant...
by Lucy Papachristou | Sep 20, 2022
By Lucy Papachristou Federal legislative overhaul of the healthcare sector is throwing a wrench into Big Pharma’s growth this fall, but companies are expected to weather the storm in a market hungry for new drug therapies. Stocks of insulin producers Eli...
